freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-27 and is reviewed periodically as new material appears.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
| Property | Value | Notes |
|---|---|---|
| Purity method | Reversed-phase HPLC | C18 column, UV detection at 214 nm |
| Identity method | Mass spectrometry | Electrospray or MALDI-TOF |
| Solubility | Soluble in water and DMSO | Dissolution may require brief mixing |
| Storage temperature | -20 °C or lower | Desiccated and protected from light |
| Counterion form | Trifluoroacetate or acetate | Affects measured peptide content |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
== Research == Researchers have explored the potential of teicoplanin as an antiviral agent against various viruses, including SARS-CoV-2. Laboratory studies indicate that teicoplanin inhibits cathepsin L, a host cell protease utilized by SARS-CoV-2 for cell entry via the endocytic pathway. In vitro experiments have demonstrated teicoplanin's ability to reduce SARS-CoV-2 infection, with reported IC50 values in the low micromolar range. This suggests potential efficacy against various SARS-CoV-2 variants due to conserved cathepsin L cleavage sites on the SARS-CoV-2 spike protein. Animal studies have also shown a protective effect against SARS-CoV-2 infection with teicoplanin pre-treatment.
=== Recreational use === Gabapentinoids produce euphoria at high doses, with effects similar to GABAergic central nervous system depressants such as alcohol, γ-hydroxybutyric acid (GHB), and benzodiazepines, and are used as recreational drugs (at 3–20 times typical clinical doses). The overall abuse potential is considered to be low and notably lower than that of other drugs such as alcohol, benzodiazepines, opioids, psychostimulants, and other illicit drugs. In any case, due to its recreational potential, pregabalin is a schedule V controlled substance in the United States. In April 2019, the United Kingdom scheduled gabapentin and pregabalin as Class C drugs under the Misuse of Drugs Act 1971, and as Schedule 3 under the Misuse of Drugs Regulations 2001. However, it is not a controlled substance in Canada, or Australia, and the other gabapentinoids, including phenibut, are not controlled substances either. As such, they are mostly legal intoxicants. Tolerance to gabapentinoids is reported to develop very rapidly with repeated use, although to also dissipate quickly upon discontinuation, and withdrawal symptoms such as insomnia, nausea, headache, and diarrhea have been reported. More severe withdrawal symptoms, such as severe rebound anxiety, have been reported with phenibut. Because of the rapid tolerance with gabapentinoids, users often escalate their doses, while other users may space out their doses and use sparingly to avoid tolerance.
=== Alcohol dependence === Nalmefene is used in the European Union to reduce alcohol dependence and NICE recommends the use of nalmefene to reduce alcohol consumption in combination with psychological support for people who drink heavily. Based on a meta analysis, the usefulness of nalmefene for alcohol dependence is unclear. Nalmefene, in combination with psychosocial management, may decrease the amount of alcohol drunk by people who are alcohol dependent. The medication may also be taken "as needed", when a person feels the urge to consume alcohol.
Sources: en.wikipedia.org
== Classification == All enzymes are assigned an Enzyme Commission number based on the chemical reaction they catalyze. An EC number functions to clear up any confusion that arises due to the fact that many enzymes have several different names that can refer to them. Lysine carboxypeptidase's EC number is 3.4.17.3. The first number in an EC number indicates the main class that the enzyme belongs to (the options being oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases). Lysine carboxypeptidase belongs to class 3 which indicates that it is a hydrolase. Hydrolases use water to break apart chemical bonds including, but not limited to, carbon-oxygen, carbon-nitrogen, and carbon-carbon bonds. The second number describes the type of bond that is broken apart in the specific enzyme catalyzed reaction. The "4" places lysine carboxypeptidase in the "peptidase" subclass. This means that this enzyme acts on peptide bonds. The third number (the sub-subclass) gives more information about the catalytic mechanism of the reaction. Lysine carboxypeptidase is in sub-subclass 17: metallocarboxypeptidases. This subclass first defines lysine carboxypeptidase as an exopeptidase (sub-subclasses 11 and 13-19) which means that it only acts on terminal bonds of a polypeptide chain. It is more specifically a carboxypeptidase (sub-subclasses 16-18) which acts on a C-terminus to break off one amino acid. The overall category of metallocarboxypeptidases indicates that it functions using metal ion catalysis.
A Russian study from 1991 showed that picamilon permeated the blood–brain barrier in cats and increased cerebral blood flow. Further work showed it crosses the blood-brain barrier in mice and rats. It is believed that picamilon is hydrolyzed into GABA and niacin, similar to the way tocopheryl nicotinate (vitamin E nicotinate) is hydrolyzed. GABA in the brain would activate GABA receptors, which in theory should have an anxiolytic effect. The second released component, niacin, is a vasodilator. A 2023 assay study showed that picamilon itself is inactive against 50 biological targets, including GABA receptors, despite being a GABA analogue.
Due to the potential for widespread usage and the evolving needs of researchers, many different mutants of GFP have been engineered. The first major improvement was a single point mutation (S65T) reported in 1995 in Nature by Roger Tsien. This mutation dramatically improved the spectral characteristics of GFP, resulting in increased fluorescence, photostability, and a shift of the major excitation peak to 488 nm, with the peak emission kept at 509 nm. This matched the spectral characteristics of commonly available FITC filter sets, increasing the practicality of use by the general researcher. A 37 °C folding efficiency (F64L) point mutant to this scaffold, yielding enhanced GFP (EGFP), was discovered in 1995 by the laboratories of Thastrup and Falkow. EGFP allowed the practical use of GFPs in mammalian cells. EGFP has an extinction coefficient (denoted ε) of 55,000 M−1cm−1. The fluorescence quantum yield (QY) of EGFP is 0.60. The relative brightness, expressed as ε•QY, is 33,000 M−1cm−1. The widely used EGFP sequence, however, may produce an unintended protein product, using the +2 frame as the template. Superfolder GFP (sfGFP), a series of mutations that allow GFP to rapidly fold and mature even when fused to poorly folding peptides, was reported in 2006. Many other mutations have been made, including color mutants; in particular, blue fluorescent protein (EBFP, EBFP2, Azurite, mKalama1), cyan fluorescent protein (ECFP, Cerulean, CyPet, mTurquoise2), and yellow fluorescent protein derivatives (YFP, Citrine, Venus, YPet).
Sources: en.wikipedia.org
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.
Trifluoroacetate and acetate are common in lyophilized peptide preparations. They contribute to the mass of the powder without contributing to the peptide itself. This shifts the true content and can affect results in biological assays.
Hydrolysis and oxidation are the primary pathways. Alkaline conditions accelerate hydrolytic cleavage of the chain. Oxidation most often involves susceptible residues, producing products that appear as earlier or later peaks in chromatographic analysis.
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。